By Fineline Cube 
French pharmaceutical giant Sanofi (NASDAQ: SNY) is set to acquire US-based Vigil Neuroscience, Inc., a clinical-stage biotech focused on developing novel therapies for neurodegenerative diseases. This strategic move is expected to significantly enhance Sanofi’s early-stage pipeline in neurology, one of its four strategic disease areas.
Acquisition Details
The acquisition includes VG-3927, an oral small molecule TREM2 agonist currently slated for Phase II study in Alzheimer’s disease. This addition to Sanofi’s portfolio underscores the company’s commitment to advancing treatments for neurodegenerative conditions.
Previous Investment
Sanofi initially invested USD 40 million in Vigil in June of last year, securing the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialize VG-3927. This early investment highlights Sanofi’s proactive approach to securing promising assets in its strategic focus areas.-Fineline Info & Tech